What Trestle Biotherapeutics does

Trestle Biotherapeutics, Inc. is a San Diego-based, preclinical-stage biotechnology company founded in 2020-2021 by Ben Shepherd, PhD (CEO) and Alice Chen, PhD (CSO), both former Organovo R&D leaders, with Bob Baltera (formerly CEO of Amira Pharmaceuticals and 17-year Amgen veteran) serving as Executive Chairman. The company is developing implantable bioengineered kidney tissues derived from human pluripotent stem cells and fabricated through 3D bioprinting, intended to restore renal function in patients with end stage renal disease (ESRD), eliminate dialysis dependency, and ultimately serve as replacement organs. The platform integrates dual-licensed foundational technologies: 3D biofabrication methods from Harvard's Wyss Institute, SEAS, and Brigham and Women's Hospital, and specialized kidney cell differentiation methods from Kumamoto University.

Trestle operates without a commercial product or revenue, relying on a combination of accelerator funding (Y Combinator W21 cohort), non-dilutive grant capital (KidneyX Artificial Kidney Prize Phase 2, $1M in June 2023), and program-based consortium support (Wellcome Leap HOPE, a $50M organ bioengineering initiative). In March 2025 the company added a research collaboration with Humacyte to incorporate FDA-approved acellular tissue engineered vessel (ATEV) technology for vascularization, addressing the principal translational bottleneck for thick-tissue organ engineering. The intended go-to-market is direct engagement with hospitals, transplant centers, and nephrology-specialized healthcare systems; no pricing or reimbursement model is disclosed given the preclinical stage.

The competitive position rests on a tightly scoped IP stack, a credentialed founding team and advisory board (including Harvard's Jennifer A. Lewis and Humacyte's Laura Niklason), and integration into multi-institutional organ-engineering consortia. Headcount is 1-10 employees, the company is privately held, and it has not yet entered clinical trials or filed an IND. Customer concentration is not yet a commercial concern; the relevant near-term risks are scientific (nephron maturation, vascularization, immune compatibility), regulatory (FDA tissue engineering standards), and capital (no disclosed institutional venture round).

Name

Trestle Biotherapeutics

Legal name

Trestle Biotherapeutics, Inc.

Website

https://trestlebio.com

Company type

Private

Founded year

2021

Operating status

Operating

Headcount range

1–10 employees

Short description

Trestle Biotherapeutics is a preclinical-stage San Diego biotech developing implantable, stem cell-derived bioengineered kidney tissues using 3D bioprinting to restore renal function in end stage renal disease patients and eliminate dialysis dependency.

Ownership category

akta.pro rank

Product category

Bioengineered Kidney Therapeutics

NAICS

Blood and Organ Banks (621991)

SIC

Pharmaceutical Preparations (2834)

akta.pro primary industry

Renal Transplant Medicine (Pre/Post-Transplant Care) (HLAKAHAD)

akta.pro secondary industry

Organoids & Organ-on-Chip (regenerative models) (HLAAAGAD)

Keywords

• Bioengineered kidney tissues
• Regenerative medicine therapeutics
• 3D bioprinting technology
• Stem cell therapy
• End stage renal disease

Headquarters

HQ city

San Diego

HQ country

United States

HQ region

North America

Offices1 record

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Personnel, Technology or R&D, Operations

Distribution channels1 record

Marketing channels4 records

Core offering

Trestle Biotherapeutics is developing implantable bioengineered kidney tissues derived from human pluripotent stem cells using 3D biofabrication technology. The product is intended for patients with end stage renal disease (ESRD) to restore renal function, eliminate dialysis dependency, delay need for transplantation, and ultimately serve as replacement organs. The company is currently in the pre-clinical R&D stage and has not yet entered clinical trials.

Product overview

Trestle Biotherapeutics is developing a single core therapeutic product: bioengineered kidney tissues. The company's approach integrates stem cell biology and 3D biofabrication technologies to create implantable tissues derived from human pluripotent stem cells. These bioengineered tissues are designed to supplement and replace lost renal function in end stage renal disease (ESRD) patients, with the goal of getting patients off dialysis, delaying the need for transplantation, and ultimately serving as replacement organs. The company licenses foundational technologies from Harvard University's Wyss Institute and Kumamoto University for stem cell differentiation and 3D biofabrication.

Differentiator

Problem solved

Functional benefit

Products and services

• Bioengineered Kidney Tissues Implantable therapeutic tissue developed using stem cell biology and 3D biofabrication, designed to be administered to kidney failure patients to restore renal function sufficient to eliminate dialysis dependency, delay need for transplantation, and serve as replacement organs. Targeted at the 785,000 ESRD patients in the US and approximately 550,000 dialysis-dependent patients.

Quantifiable outcome

• 5-year survival for dialysis patients under 40%
• +2 more outcomes

Segments1 record

Ideal customer profiles2 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature3 records

Partnerships

Four partnerships are on record, tiered core.

• HumacytecoreStrategic or Co-development Partner · 6 March 2025Research collaboration and material transfer agreement to explore technology synergies combining Trestle's bioengineered kidney tissues with Humacyte's FDA-approved acellular tissue engineered vessel (ATEV) technology, with the goal of creating a vascularized bioengineered kidney for transplantation. The collaboration aims to address organ shortage affecting ~100,000 U.S. transplant waiting list patients and 600,000+ dialysis-dependent patients.
• Wellcome LeapcoreStrategic or Co-development Partner · 25 May 2023Trestle joined the Wellcome Leap HOPE (Human, Organs, Physiology & Engineering) program, a $50M initiative focused on bioengineering complex human organs. Trestle integrates its developmental & stem cell biology and 3D biofabrication expertise with other HOPE performers led by Jennifer Lewis of Harvard to develop bioengineered kidney tissues for ESRD patients.
• Kumamoto UniversitycoreOEM/ Whitelabel/ Licensing Partner · 15 February 2022License agreement with Kumamoto University for foundational methods for the generation of specialized kidney cell types from human pluripotent stem cells, a key technology for regenerative medicine applications.
• Harvard UniversitycoreOEM/ Whitelabel/ Licensing Partner · 8 February 2022License agreement with Harvard University to commercialize stem cell- and 3D biofabrication-based regenerative medicine technologies developed at Harvard's Wyss Institute for Biologically Inspired Engineering, Harvard John A. Paulson School of Engineering and Applied Sciences (SEAS), and Brigham and Women's Hospital.

Scale indicators7 records

Recent moves6 records

Expansion highlights5 records

Broad incumbents

• United Therapeutics: Public biotech with a dedicated xenotransplantation and bioengineered organ program (Revivicor subsidiary developing GalSafe and 10-GE pig kidneys) pursuing the same ESRD patient population. Highly relevant broad incumbent with deeper capital and nearer-term clinical timelines.
• Organovo: Pioneering 3D bioprinting company where Trestle's co-founders (Ben Shepherd, Alice Chen) previously led R&D. Comparable technology platform (3D bioprinted human tissues) and lineage make it a direct heritage peer, though Organovo is now focused on disease modeling rather than therapeutic implantation.
• MiMedx: Public regenerative medicine company commercializing placental tissue allografts for wound care, surgical, and regenerative applications. Comparable in being a tissue-engineering commercial-stage company, though focused on non-organ tissue therapeutics.
• Vertex Pharmaceuticals: Large-cap biopharma advancing VX-880/VX-264 stem cell-derived islet therapies for type 1 diabetes, with clinical proof-of-concept in cell-based organ-replacement therapeutics. Relevant broad incumbent demonstrating the regulatory and clinical pathway Trestle will eventually need to traverse with a different organ.

Direct peers

• Humacyte: Commercial-stage tissue engineering company with an FDA-approved acellular tissue engineered vessel (ATEV) and pipeline in bioengineered tissues. Trestle's 2025 collaborator and the closest direct peer in modality (implantable engineered tissue) and stage-evolution.
• ProKidney: Late-stage clinical cell-therapy company developing autologous cell therapy (Renal Autologous Cell Therapy, REACT) for CKD/ESRD. Direct peer targeting the same end-stage renal disease market via a different regenerative modality.
• eGenesis: Developer of gene-edited pig kidneys for transplantation into ESRD patients. Closest direct competitor in solving kidney failure via a regenerative/organ-replacement modality, with active clinical programs.

Emerging players

• Aspect Biosystems: Canada-based 3D bioprinting platform company developing therapeutic tissue therapeutics (notably pancreatic islets for type 1 diabetes). Directly comparable technology modality - microfluidic 3D bioprinting of implantable human tissue therapeutics - applied to a different organ but indicative of the same platform race Trestle is in.
• LyGenesis: Clinical-stage company using ex vivo organ bioreactor technology to grow ectopic functional livers in lymph nodes, with extension programs toward other organs. Relevant emerging peer pursuing in-situ organ engineering for organ failure.
• Curi Bio: Developer of human iPSC-derived tissues and organoid platforms for therapeutic and drug-discovery applications. Adjacent emerging peer working at the intersection of stem cell biology and engineered tissue, with overlap in iPSC-derived kidney cell expertise.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks6 records

Key highlights7 records

Customer concentration

• LinkedInlinkedin.com/company/trestle-biotherapeutics

Revenue estimate

Valuation estimate

Number of profiles

Profiles4 records

Funding overview

Funding rounds3 records

Investors6 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Trestle Biotherapeutics